{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:18:03Z","timestamp":1792009083541,"version":"4.4.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic autoimmune illness characterized by demyelination, neurodegeneration, and inflammation in the central nervous system. The AXL gene, which codes for a receptor tyrosine kinase, has emerged as a promising therapeutic target due to its involvement in neuroinflammation and oligodendrocyte dysfunction. In the current study, we employed <jats:italic>in silico<\/jats:italic> techniques to design Antisense Oligonucleotides (ASOs) that selectively target AXL gene transcripts to modulate AXL expression and mitigate MS pathology. Three ASOs, A1, A2, and A3, were designed to specifically target the 5\u2032 untranslated region (5\u2032UTR) and coding region of the AXL gene transcripts. The ASOs were optimized with a focus on stability, binding affinity, and specificity towards AXL mRNA while minimizing off-target effects. To investigate ASO-mRNA interactions and gauge their ability to alter AXL expression, Molecular Docking was performed. Our analyses showed that A1, A2, and A3 had substantial interactions with AXL mRNA, with binding affinities of \u22129.5\u00a0kcal\/mol, \u221210.8\u00a0kcal\/mol, and \u221210.6\u00a0kcal\/mol, respectively. The targeting of AXL gene transcripts through ASOs shows promise in reducing MS symptoms. Precision ASO-based therapies could effectively manage MS by targeting the essential pathways involved in the disease. ASOs provide a highly targeted approach for treating MS and offer a precise therapeutic strategy for this debilitating condition. The study lays the groundwork for future <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> studies to confirm the therapeutic potential of these ASOs for the treatment of MS.<\/jats:p>","DOI":"10.3389\/fchem.2025.1548269","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:35:37Z","timestamp":1738740937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management"],"prefix":"10.3389","volume":"13","author":[{"given":"Bhargav","family":"Shreevatsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigna","family":"Nagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Dharmashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Harendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddesh V.","family":"Siddalingegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen A.","family":"Al-Mazroua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh F.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashanka K.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekar","family":"Srinivasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Shivamallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Prasad","family":"Kollur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.3389\/fimmu.2019.01921","article-title":"Combination of cannabinoids, \u03949- tetrahydrocannabinol and cannabidiol, ameliorates experimental multiple sclerosis by suppressing neuroinflammation through regulation of miRNA-mediated signaling pathways","volume":"10","author":"Al-Ghezi","year":"2019","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10571-021-01158-4","article-title":"Nucleic acids as novel therapeutic modalities to address multiple sclerosis onset and progression","volume":"42","author":"Baharlooi","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"11994","DOI":"10.1074\/jbc.272.18.11994","article-title":"2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells","volume":"272","author":"Baker","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/ijms17111807","article-title":"The Gas6\/TAM system and multiple sclerosis","volume":"17","author":"Bellan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.4103\/0972-2327.164814","article-title":"Epidemiology and genetic aspects of multiple sclerosis in India","volume":"18","author":"Bhatia","year":"2015","journal-title":"Ann. Indian Acad. Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4939-6433-8_13","article-title":"Automated RNA 3D structure prediction with RNAComposer","volume":"1490","author":"Biesiada","year":"2016","journal-title":"Methods Mol. Biol. Clift. N.J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1042\/BJ20041956","article-title":"Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi","volume":"388","author":"Bilanges","year":"2005","journal-title":"Biochem. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense oligonucleotides for the study and treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"W135","DOI":"10.1093\/nar\/gkh449","article-title":"Sfold web server for statistical folding and rational design of nucleic acids","volume":"32","author":"Ding","year":"2004","journal-title":"Nucleic acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/01.wco.0000227035.93199.e0","article-title":"Emerging therapeutic targets in multiple sclerosis","volume":"19","author":"Fontoura","year":"2006","journal-title":"Curr. Opin. neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn917","article-title":"Why does remyelination fail in multiple sclerosis?","volume":"3","author":"Franklin","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis--the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1038\/sj.onc.1202788","article-title":"Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras","volume":"18","author":"Goruppi","year":"1999","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.csbj.2019.07.008","article-title":"In-silico design of DNA oligonucleotides: challenges and approaches","volume":"17","author":"Hendling","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41598-017-01348-5","article-title":"Three-dimensional modeling of single stranded DNA hairpins for aptamer-based biosensors","volume":"7","author":"Jeddi","year":"2017","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/prot.21117","article-title":"PIPER: an FFT-based protein docking program with pairwise potentials","volume":"65","author":"Kozakov","year":"2006","journal-title":"Proteins"},{"key":"B22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"941528","DOI":"10.3389\/fnmol.2022.941528","article-title":"Cerebral organoids and antisense oligonucleotide therapeutics: challenges and opportunities","volume":"15","author":"Lange","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"a009076","DOI":"10.1101\/cshperspect.a009076","article-title":"Biology of the TAM receptors","volume":"5","author":"Lemke","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1074\/jbc.270.2.551","article-title":"The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage","volume":"270","author":"O\u2019Bryan","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Mol. Basel, Switz."},{"key":"B30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0165-5728(97)00073-8","article-title":"The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion1Presented at the Albert Einstein College of Medicine, Bronx, NY, on February 3, 1997 in honor of the retirement of Dr. William T. Norton, a pioneer neurochemist in the myelin\/oligodendrocyte arena.1","volume":"77","author":"Raine","year":"1997","journal-title":"J. Neuroimmunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1073\/pnas.95.4.1460","article-title":"A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics","volume":"95","author":"SantaLucia","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: a primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Genetics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/0092-8674(95)90520-0","article-title":"The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3\/Axl family of receptor tyrosine kinases","volume":"80","author":"Stitt","year":"1995","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","article-title":"The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored","volume":"39","author":"Szklarczyk","year":"2011","journal-title":"Nucleic acids Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.7759\/cureus.24895","article-title":"Multiple sclerosis: therapeutic strategies on the horizon","volume":"14","author":"Talanki Manjunatha","year":"2022","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"33335","DOI":"10.1074\/jbc.M111.263020","article-title":"Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C\u03b4, and p38 mitogen-activated protein kinase (MAPK)","volume":"286","author":"Thorp","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4103\/1673-5374.177714","article-title":"Gas6-Tyro3 signaling is required for Schwann cell myelination and possible remyelination","volume":"11","author":"Torii","year":"2016","journal-title":"Neural Regen. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"724718","DOI":"10.3389\/fphar.2021.724718","article-title":"Progress in the application of drugs for the treatment of multiple sclerosis","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2353\/ajpath.2009.080807","article-title":"Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions","volume":"175","author":"Weinger","year":"2009","journal-title":"Am. J. pathology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jneuroim.2017.03.015","article-title":"Multiple sclerosis in India: iceberg or volcano","volume":"307","author":"Zahoor","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic acids Res."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1548269\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:35:41Z","timestamp":1738740941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1548269\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":44,"alternative-id":["10.3389\/fchem.2025.1548269"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2025.1548269","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"article-number":"1548269"}}